Monospecific and bispecific genera are of special concern as they represent unique phylogenetic/evolutionary trajectories within larger clades. In addition, as phylogenetically older taxa are supposed to be exposed to higher rarity and extinction risk, monospecific and bispecific genera may be intrinsically more prone to extinction risks than multispecies genera, although extinction risks also depend on the ecological and biological strategy of the species. Here, the distribution across biogeographical zones and the levels of threat to 2 speciose orders of mammals (monospecific and bispecific genera of Rodentia and Soricomorpha) are investigated in order to highlight major patterns at the worldwide scale. In Rodentia, 39.7% of the genera (n = 490) were monospecific and 17.9% were bispecific. In Soricomorpha, 44.4% of the total genera (n = 45) were monospecific and 15% were bispecific. There was a positive correlation between the number of monospecific genera and the total number of genera per family. Peaks of monospecific and bispecific genera richness were observed in Neotropical, Oriental and Afrotropical regions in rodents and in the Palearctic region in soricomorphs. Range size was significantly uneven across biogeographic region in rodents (with larger ranges in Nearctic and Oriental regions and smaller ranges in the Australian region), but there was no difference across biogeographic regions in terms of range size in soricomorphs. Most of the monospecific and bispecific genera occurred in forest habitat in both taxa. The frequency distribution of the monospecific and bispecific genera across IUCN categories did not differ significantly from the expected pattern using the total rodent genera and the multispecies genera.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/1749-4877.12266 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A brain-penetrant bispecific antibody lowers oligomeric alpha-synuclein and activates microglia in a mouse model of alpha-synuclein pathology.
Neurotherapeutics
December 2024
Department of Public Health and Caring Sciences, Uppsala University, 751 85, Uppsala, Sweden. Electronic address:
Parkinson's disease (PD) is characterized by a progressive loss of dopaminergic neurons, linked to aggregation of alpha-synuclein (αSYN) into Lewy bodies. Current treatments are symptomatic and do not halt or reverse the neurodegeneration. Immunotherapy targeting aggregated αSYN shows potential, but therapeutic efficacy is limited by poor brain penetration of antibodies.
View Article and Find Full Text PDFFacilitating high throughput bispecific antibody production and potential applications within biopharmaceutical discovery workflows.
MAbs
December 2024
Large Molecule Discovery, GSK, GSK Medicines Research Centre, Stevenage, UK.
A major driver for the recent investment surge in bispecific antibody (bsAb) platforms and products is the multitude of distinct mechanisms of action that bsAbs offer compared to a combination of two monoclonal antibodies. Four bsAb products were granted first regulatory approvals in the US or EU during 2023 and the biopharmaceutical industry pipeline is brimming with bsAb candidates across a broad range of therapeutic applications. In previously reported bsAb discovery campaigns, following a hypothesis-based choice of two specific target proteins, selections and screening activities have often been performed in mono-specific formats.
View Article and Find Full Text PDFNovel tri-specific T-cell engager targeting IL-13Rα2 and EGFRvIII provides long-term survival in heterogeneous GBM challenge and promotes antitumor cytotoxicity with patient immune cells.
J Immunother Cancer
December 2024
Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, Pennsylvania, USA
Article Synopsis
- Glioblastoma multiforme (GBM) presents a challenge for treatment due to its antigenic variability, prompting researchers to develop multivalent immunotherapies that target multiple tumor antigens to improve effectiveness.
- The study introduces a new class of antibodies called DNA-encoded tri-specific T-cell engagers (DTriTEs) that target two specific GBM antigens and engage T cells, showing promising in vitro and in vivo results.
- The leading DTriTE construct, DT2035, not only significantly reduced tumor burden and improved survival rates in mouse models but also showed sustained expression and induced strong immune responses, making it a potential game-changer for GBM treatment.
Intra-channel bi-epitopic crosslinking unleashes ultrapotent antibodies targeting Na1.7 for pain alleviation.
Cell Rep Med
November 2024
School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Tsinghua University, Beijing 100084, China. Electronic address:
Crucial for cell activities, ion channels are key drug discovery targets. Although small-molecule and peptide modulators dominate ion channel drug discovery, antibodies are emerging as an alternative modality. However, challenges persist in generating potent antibodies, especially for channels with limited extracellular epitopes.
View Article and Find Full Text PDFPreventing osteoporotic bone loss in mice by promoting balanced bone remodeling through M-CSF, a dual antagonist to c-FMS and αvβ3 receptors.
Int J Biol Macromol
December 2024
Department of Physiology and Cell Biology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel. Electronic address:
Osteoporosis is a common, age-related disease caused by imbalanced bone remodeling. Current treatments either shut down bone resorption or robustly stimulate bone formation. Here, we describe a novel compound that inhibits osteoclast activity without causing apparent disruptions to bone formation by targeting both c-FMS (i.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!